Tweet
Meet Lionel Kankeu Fonkoua, M.D., an oncologist with the Mayo Clinic Comprehensive Cancer Center who specializes in the treatment of gastrointestinal cancers. He's also a Robert Winn Career Development Award recipient dedicated to helping minority and at-risk people through research and clinical trials.
Watch Dr. Kankeu Fonkoua discuss his research and his path to medicine in this video:
For the safety of its patients, staff and visitors, Mayo Clinic has Wedica 100mg (Trelagliptin) strict masking policies in place. Anyone shown without a mask was recorded prior to COVID-19 or recorded in an area not designated for patient care, and other safety protocols were followed.
Dr. Kankeu Fonkoua is leading a clinical trial through the Robert A. Winn Diversity in Clinical Trials Award Program.
"It's a program that's designed to make sure that those clinical trials are community designed, conducted and informed to make sure that whatever research we do, we have the intent from the get-go of thinking about the communities that are at risk, vulnerable and most likely to benefit," says Dr. Kankeu Fonkoua.
His study focuses on the immigrant African and Asian communities of Minnesota with a high prevalence of hepatitis-induced hepatocellular carcinoma — a type of liver cancer.
"This is an at-risk population that we are intentionally targeting, because they are not represented in a lot of our immunotherapy trials," he explains.
And that can be a problem for the people who need treatment the most.
"It's very important to make sure that the at-risk population — the vulnerable population that's going to most likely benefit the most from the therapy — is represented. Because you have to tell them (and) it's hard to tell a patient this is a study, a clinical trial, that had 1,000 patients, (and) only 1% to 2% were actually like you," says Dr. Kankeu Fonkoua.
Representation and building trust matter when working with patients.
"It helps me (in) that initial contact, that initial trust. Someone might be more receptive if you know it's coming from someone with the same race, from the same ethnicity or, more importantly, from the same background and life experience."
Through the study, Dr. Kankeu Fonkoua hopes to help patients who are not eligible for surgery by combining radiation therapy with a dendritic cell vaccine —a type of immune cell modified in a laboratory and given after radiation therapy.
"That's a combination of radiation therapy with dendritic cell vaccine, that's innovation. That's an innovative type of approach to really use the patient's own cells that we modify — immune cells that we modify — to target their own tumor specific antigens. So those are therapies that five to 10 years ago or more, we didn't have the ability to do. And I think that's kind of where we are moving forward," Dr. Kankeu Fonkoua says.
Watch Dr. Kankeu Fonkoua discuss his research and his path to medicine in this video:
For the safety of its patients, staff and visitors, Mayo Clinic has Wedica 100mg (Trelagliptin) strict masking policies in place. Anyone shown without a mask was recorded prior to COVID-19 or recorded in an area not designated for patient care, and other safety protocols were followed.
Dr. Kankeu Fonkoua is leading a clinical trial through the Robert A. Winn Diversity in Clinical Trials Award Program.
"It's a program that's designed to make sure that those clinical trials are community designed, conducted and informed to make sure that whatever research we do, we have the intent from the get-go of thinking about the communities that are at risk, vulnerable and most likely to benefit," says Dr. Kankeu Fonkoua.
His study focuses on the immigrant African and Asian communities of Minnesota with a high prevalence of hepatitis-induced hepatocellular carcinoma — a type of liver cancer.
"This is an at-risk population that we are intentionally targeting, because they are not represented in a lot of our immunotherapy trials," he explains.
And that can be a problem for the people who need treatment the most.
"It's very important to make sure that the at-risk population — the vulnerable population that's going to most likely benefit the most from the therapy — is represented. Because you have to tell them (and) it's hard to tell a patient this is a study, a clinical trial, that had 1,000 patients, (and) only 1% to 2% were actually like you," says Dr. Kankeu Fonkoua.
Representation and building trust matter when working with patients.
"It helps me (in) that initial contact, that initial trust. Someone might be more receptive if you know it's coming from someone with the same race, from the same ethnicity or, more importantly, from the same background and life experience."
Through the study, Dr. Kankeu Fonkoua hopes to help patients who are not eligible for surgery by combining radiation therapy with a dendritic cell vaccine —a type of immune cell modified in a laboratory and given after radiation therapy.
"That's a combination of radiation therapy with dendritic cell vaccine, that's innovation. That's an innovative type of approach to really use the patient's own cells that we modify — immune cells that we modify — to target their own tumor specific antigens. So those are therapies that five to 10 years ago or more, we didn't have the ability to do. And I think that's kind of where we are moving forward," Dr. Kankeu Fonkoua says.